Skip to content

Optimal Strategy for Repair of Type A Acute Aortic Dissection

Searching Optimal Tailored Strategy for Repair of Acute Type A Acute Aortic Dissection

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05912608
Acronym
TARAD
Enrollment
900
Registered
2023-06-22
Start date
2024-01-01
Completion date
2026-12-31
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Dissection

Keywords

Type A Acute Aortic Dissection (TAAAD), Root-Sparing Replacement, Hemiarch Procedures, Ascending Aorta Replacement, Total Arch Replacement (TARP), Frozen Elephant Trunk (FET)

Brief summary

Acute type A aortic dissection (TAAD) persists as a clinicopathologic entity with high lethality in the current era. Several procedures are presently used to repair the TAAAD. The objective of this study is to analyze two groups of individuals using a conservative approach through root-sparing and hemiarch techniques in patients who are hospitalized in higher-risk clinical conditions or more aggressive procedures such as root replacement and total arch replacement in low-risk patients.

Detailed description

The target population enrolled in the registry includes patients with TAAAD.The high volume of patients that will be enrolled in this registry will receive proximal and distal aortic repair in elective, urgent or emergency clinical condition. Efforts of investigators will be concentrated in TAAAD repair using a conservative approach of root preservation and hemiarch reconstruction in the majority of patients who will be referred in critical clinical condition. High-risk patients with older age or more comorbidities had more conservative repairs to limit surgical insult to these complicated patients. Total arch reconstruction and root replacement will be optional procedures for specific subgroups of patients who may benefit from a more complex index finger operation without incurring additional immediate risk. Investigators hope to demonstrate a reduction in operative mortality and an improvement in early and late outcomes. The experience of investigators will be summarized in an algorithm for TAAAD repair with an analysis of early morbidity and mortality, as well as late survival and no reoperation.

Interventions

PROCEDUREConservative TAAAD-R

Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.

PROCEDUREExtensive TAAAD-R

Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).

Sponsors

Centre Cardiologique du Nord
Lead SponsorOTHER
Henri Mondor University Hospital
CollaboratorOTHER
Universita degli Studi di Genova
CollaboratorOTHER
Pitié-Salpêtrière Hospital
CollaboratorOTHER
Ospedale San Camillo, Rome, Italy
CollaboratorUNKNOWN

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* TAAD or intramural hematoma involving the ascending aorta * Patients aged \> 18 years * Symptoms started within 7 days from surgery * Primary surgical repair of acute TAAD * Any other major cardiac surgical procedure concomitant with surgery for TAAD.

Exclusion criteria

* Patients aged \< 18 years * Onset of symptoms \> 7 days from surgery * Prior procedure for TAAD * Concomitant endocarditis; * TAAD secondary to blunt or penetrating chest trauma.

Design outcomes

Primary

MeasureTime frameDescription
Operative Mortality (OM)30-dayPatients who died within 30 days
Rate of Transient Neurologic Deficit (TND)30-dayNumber of participants who will complicate postoperatively with episode of TND which will include complication rate such as confusion, delirium, agitation
Rate of permanent Neurologic Deficit (PND)30-dayNumber of participants with acute episode of a focal or global neurological deficit. Rates of alteration of degree of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopsia, amaurosis fugax. To consider rate of other neurologic signs or symptoms consistent with stroke duration of focal or global neurologic deficit greater than 24 hours.

Secondary

MeasureTime frameDescription
Rate of perioperative Myocardial Infarction (MI)30-dayNumber of participants with MI based on fourth universal definition.
Rate of spinal Cord Injury (SCI)30-dayNumber of participants with SCI intended as rate of paraplegia and/or paraparesis
Rate of composite of Major Adverse Events (MAE)30-dayNumber of participants with MAE which will include the composite rate of myocardial infarction, cerebrovascular accident, need for dialysis, or need for tracheostomy according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE)
Rate of composite of Major Adverse Pulmonary Events (MAPE)30-dayNumber of participants with MAPE which will include the composite rate of intubation \>48 hours, pneumonia, reintubation, tracheostomy according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE)
Rate of reintervention10 yearsThe number of participants who will require reoperation for the aortic valve, proximal aorta, or distal aorta.
Late survival10 yearsThe secondary endpoint of the study is the evaluation of late survival

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFrancesco Nappi

Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis, Paris, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026